These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

535 related articles for article (PubMed ID: 25953646)

  • 1. Heritability of Biomarkers of Oxidized Lipoproteins: Twin Pair Study.
    Rao F; Schork AJ; Maihofer AX; Nievergelt CM; Marcovina SM; Miller ER; Witztum JL; O'Connor DT; Tsimikas S
    Arterioscler Thromb Vasc Biol; 2015 Jul; 35(7):1704-11. PubMed ID: 25953646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. OxPL/apoB, lipoprotein(a) and OxLDL biomarkers and cardiovascular disease in chronic hemodialysis patients.
    Bossola M; Tazza L; Luciani G; Tortorelli A; Tsimikas S
    J Nephrol; 2011; 24(5):581-8. PubMed ID: 21404224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial.
    Fraley AE; Schwartz GG; Olsson AG; Kinlay S; Szarek M; Rifai N; Libby P; Ganz P; Witztum JL; Tsimikas S;
    J Am Coll Cardiol; 2009 Jun; 53(23):2186-96. PubMed ID: 19497447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein.
    Tsimikas S; Lau HK; Han KR; Shortal B; Miller ER; Segev A; Curtiss LK; Witztum JL; Strauss BH
    Circulation; 2004 Jun; 109(25):3164-70. PubMed ID: 15184281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial.
    Tsimikas S; Witztum JL; Miller ER; Sasiela WJ; Szarek M; Olsson AG; Schwartz GG;
    Circulation; 2004 Sep; 110(11):1406-12. PubMed ID: 15353498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxidized low-density lipoprotein biomarkers in patients with end-stage renal failure: acute effects of hemodialysis.
    Bossola M; Tazza L; Merki E; Giungi S; Luciani G; Miller ER; Lin EB; Tortorelli A; Tsimikas S
    Blood Purif; 2007; 25(5-6):457-65. PubMed ID: 18075247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of oxidized phospholipids, lipoprotein (a) and biomarkers of oxidized lipoproteins in chronically occluded coronary arteries in sudden cardiac death and following successful percutaneous revascularization.
    Fefer P; Tsimikas S; Segev A; Sparkes J; Otsuka F; Kolodgie F; Virmani R; Juliano J; Charron T; Strauss BH
    Cardiovasc Revasc Med; 2012; 13(1):11-9. PubMed ID: 22079685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxidized low-density lipoprotein in children with familial hypercholesterolemia and unaffected siblings: effect of pravastatin.
    Rodenburg J; Vissers MN; Wiegman A; Miller ER; Ridker PM; Witztum JL; Kastelein JJ; Tsimikas S
    J Am Coll Cardiol; 2006 May; 47(9):1803-10. PubMed ID: 16682304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between biomarkers of oxidized low-density lipoprotein, statin therapy, quantitative coronary angiography, and atheroma: volume observations from the REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) study.
    Choi SH; Chae A; Miller E; Messig M; Ntanios F; DeMaria AN; Nissen SE; Witztum JL; Tsimikas S
    J Am Coll Cardiol; 2008 Jul; 52(1):24-32. PubMed ID: 18582631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-year prospective results from the Bruneck study.
    Tsimikas S; Kiechl S; Willeit J; Mayr M; Miller ER; Kronenberg F; Xu Q; Bergmark C; Weger S; Oberhollenzer F; Witztum JL
    J Am Coll Cardiol; 2006 Jun; 47(11):2219-28. PubMed ID: 16750687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice.
    Merki E; Graham MJ; Mullick AE; Miller ER; Crooke RM; Pitas RE; Witztum JL; Tsimikas S
    Circulation; 2008 Aug; 118(7):743-53. PubMed ID: 18663084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxidation-specific biomarkers and risk of peripheral artery disease.
    Bertoia ML; Pai JK; Lee JH; Taleb A; Joosten MM; Mittleman MA; Yang X; Witztum JL; Rimm EB; Tsimikas S; Mukamal KJ
    J Am Coll Cardiol; 2013 May; 61(21):2169-79. PubMed ID: 23541965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxidized Phospholipids and Risk of Calcific Aortic Valve Disease: The Copenhagen General Population Study.
    Kamstrup PR; Hung MY; Witztum JL; Tsimikas S; Nordestgaard BG
    Arterioscler Thromb Vasc Biol; 2017 Aug; 37(8):1570-1578. PubMed ID: 28572160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipoprotein(a), Oxidized Phospholipids, and Coronary Artery Disease Severity and Outcomes.
    Gilliland TC; Liu Y; Mohebi R; Miksenas H; Haidermota S; Wong M; Hu X; Cristino JR; Browne A; Plutzky J; Tsimikas S; Januzzi JL; Natarajan P
    J Am Coll Cardiol; 2023 May; 81(18):1780-1792. PubMed ID: 37137588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relation of oxidative biomarkers, vascular dysfunction, and progression of coronary artery calcium.
    Ahmadi N; Tsimikas S; Hajsadeghi F; Saeed A; Nabavi V; Bevinal MA; Kadakia J; Flores F; Ebrahimi R; Budoff MJ
    Am J Cardiol; 2010 Feb; 105(4):459-66. PubMed ID: 20152239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoantibodies and immune complexes to oxidation-specific epitopes and progression of aortic stenosis: Results from the ASTRONOMER trial.
    Capoulade R; Chan KL; Mathieu P; Bossé Y; Dumesnil JG; Tam JW; Teo KK; Yang X; Witztum JL; Arsenault BJ; Després JP; Pibarot P; Tsimikas S
    Atherosclerosis; 2017 May; 260():1-7. PubMed ID: 28319871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B100 and lipoprotein(a).
    Yeang C; Hung MY; Byun YS; Clopton P; Yang X; Witztum JL; Tsimikas S
    J Clin Lipidol; 2016; 10(3):594-603. PubMed ID: 27206947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lp(a), oxidized phospholipids and oxidation-specific epitopes are increased in subjects with keloid formation.
    Ruder S; Mansfield B; Immelman AR; Varki N; Miu P; Raal F; Tsimikas S
    Lipids Health Dis; 2022 Nov; 21(1):113. PubMed ID: 36320028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship of oxidized phospholipids on apolipoprotein B-100 particles to race/ethnicity, apolipoprotein(a) isoform size, and cardiovascular risk factors: results from the Dallas Heart Study.
    Tsimikas S; Clopton P; Brilakis ES; Marcovina SM; Khera A; Miller ER; de Lemos JA; Witztum JL
    Circulation; 2009 Apr; 119(13):1711-9. PubMed ID: 19307470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute impact of apheresis on oxidized phospholipids in patients with familial hypercholesterolemia.
    Arai K; Orsoni A; Mallat Z; Tedgui A; Witztum JL; Bruckert E; Tselepis AD; Chapman MJ; Tsimikas S
    J Lipid Res; 2012 Aug; 53(8):1670-8. PubMed ID: 22628616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.